Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
44.43
+1.06 (2.44%)
At close: Mar 27, 2024, 4:00 PM
44.51
+0.08 (0.18%)
After-hours: Mar 27, 2024, 7:27 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for CRNX stock have an average target of 56.25, with a low estimate of 35 and a high estimate of 80. The average target predicts an increase of 26.60% from the current stock price of 44.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRNX stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 3 |
Buy | 6 | 7 | 8 | 9 | 9 | 9 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 8 | 9 | 10 | 10 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Oppenheimer | Oppenheimer | Buy Maintains $54 → $55 | Buy | Maintains | $54 → $55 | +23.79% | Mar 20, 2024 |
JMP Securities | JMP Securities | Buy Maintains $60 → $80 | Buy | Maintains | $60 → $80 | +80.06% | Mar 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $60 | Strong Buy | Maintains | $50 → $60 | +35.04% | Mar 20, 2024 |
JonesTrading | JonesTrading | Strong Buy Maintains $52 → $56 | Strong Buy | Maintains | $52 → $56 | +26.04% | Mar 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +12.54% | Mar 19, 2024 |
Financial Forecast
Revenue This Year
11.14M
from 4.01M
Increased by 177.55%
Revenue Next Year
40.25M
from 11.14M
Increased by 261.38%
EPS This Year
-3.35
from -3.69
EPS Next Year
-3.73
from -3.35
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 107.1M | 195.4M | 485.9M | 895.3M | 1.4B |
Avg | 11.1M | 40.3M | 127.1M | 445.5M | 910.3M |
Low | n/a | 2.9M | 23.7M | 171.5M | 239.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 2,568.8% | 1,654.3% | 1,107.3% | 604.2% | 219.4% |
Avg | 177.5% | 261.4% | 215.9% | 250.4% | 104.3% |
Low | - | -73.6% | -41.1% | 34.9% | -46.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.66 | -3.08 | 1.79 | 5.90 | 10.65 |
Avg | -3.35 | -3.73 | -3.16 | 1.11 | 4.34 |
Low | -3.75 | -4.76 | -4.84 | -2.24 | -1.70 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 857.6% |
Avg | - | - | - | - | 289.9% |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.